3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Neoplasm Metastasis
3
Multiple Myeloma
2
Melanoma
2
Leukemia, Myeloid, Acute
2
Glioblastoma
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma
2
Triple Negative Breast Neoplasms
1
Thymoma
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Richter's Transformation
1
Recurrence
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Oligodendroglioma
1
Neoplasms, Plasma Cell
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Large B-Cell, Diffuse
1
Lung Neoplasms
1
Liver Neoplasms
1
Glioma
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Castration Levels of Testosterone
1
Carcinoma, Transitional Cell
1
Carcinoma, Squamous Cell
1
Carcinoma, Renal Cell
1
Interventions
Temozolomide
17
Radiotherapy
5
Bevacizumab
5
Filgrastim
4
vocimagene amiretrorepvec
3
sargramostim
3
etoposide phosphate
3
antineoplaston AS 2-1
3
antineoplaston A10
3
Surgical Procedures, Operative
3
O(6)-benzylguanine
3
Melphalan
3
Lomustine
3
Flucytosine
3
Dynamic Contrast Enhanced Magnetic Resonance Imaging
3
Carmustine
3
Aminolevulinic Acid
3
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
3
tovorafenib
2
palbociclib
2
cabozantinib
2
Vorinostat
2
Topotecan
2
Thiotepa
2
Radiotherapy, Intensity-Modulated
2
Perfusion Magnetic Resonance Imaging
2
Magnetic Resonance Spectroscopy
2
Irinotecan
2
Ifosfamide
2
Granulocyte Colony-Stimulating Factor
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Astrocytoma
×
selinexor
×
Clear all
NCT01986348
2023-01-26
KING
Karyopharm Therapeutics Inc
Phase 2
Terminated
76 enrolled
16 charts